TRK820 IN PATIENTS WITH HYPONATREMIA COINCIDENT WITH CONGESTIVE HEART FAILURE

TRK-820是一种新型的4，5-环氧-吗啡喃衍生物， 用作止痛剂。 早期临床试验使用健康 志愿者表现出意想不到的饮水效果。 此后该 TRK-820的开发已经扩展到包括考虑 该药物在治疗低钠血症中的效用 体液过多 本研究的主要目的是评估 TRK-820治疗低钠血症的有效性和安全性 符合纽约心脏协会III级或IV级心脏 失败 受试者将被给予静脉内剂量的TRK-820 或安慰剂，每天早晨一次，持续5天。 血液采样、尿液 将在整个过程中进行血液动力学测量 每个学习日。

TRK-820 is a novel 4,5 epoxy-morphinan derivative which was designed and intended for use as an analgesic. Early clinical trials using healthy volunteers demonstrated an unexpected aquaretic effect. Since then, the development of TRK-820 has been extended to include a consideration of the utility of the drug in the treatment of hyponatremia associated with fluid overload. The primary objectives of this research are to evaluate the effectiveness and safety of TRK-820 in patients with hyponatremia coincident with New York Heart Association Class III or IV heart failure. Subjects will be administered an intravenous dose of TRK-820 or placebo once each morning for 5 days. Blood sampling, urine collections, and hemodynamic measurements will be performed throughout each study day.